Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
EOSE Eos Energy Enterprises Inc
GME GameStop Corp
FTDR Frontdoor Inc
HD Home Depot Inc
SRCE 1st Source Corp
PNC PNC Financial Services Group Inc
AAPL Apple Inc
MSFT Microsoft Corp
FAZE FaZe Holdings Inc

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.


Last Trade
0.75 (0.51%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.81 (-0.54%)
B/A Size
Day's High
Day's Low

10-day average volume:

Target's stock falls toward longest losing streak in 23 years

2:09 pm ET May 31, 2023 (MarketWatch)

Shares of Target Corp. (TGT) fell 1.4% in afternoon trading Wednesday, putting them on course for the lowest close since Aug. 11, 2020. The discount retailer's stock was also headed for a ninth-straight decline, which would be the longest losing streak since the 11-day stretch that ended Feb. 24, 2000, according to Dow Jones Market Data. The current losing streak started a day after it rose 2.6% on May 17, after Target reported a fiscal first-quarter profit that beat expectations but cut its full-year outlook. On May 18, the day the losing streak started, rival Walmart Inc. (WMT) also beat quarterly profit forecasts, but one-upped Target by raising its full-year outlook. Target's stock has tumbled 18.0% during its losing streak, while Walmart shares have eased 1.8% over the same stretch. Target shares have now shed 11.4% year to date, while , Walmart's stock has gained 3.6%, the Consumer Staples Select Sector SPDR exchange-traded fund (XLP) has slipped 2.2% and the S&P 500 has advanced 9.1%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 31, 2023 14:09 ET (18:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.